Alzheimers Dement
December 2024
Background: Plasma pTau217 (tau phosphorylated at threonine 217) assays will expand access to screening for Alzheimer's disease (AD). However, clinical interpretation is not well-established, particularly during the preclinical window when interventions may be most effective. Using plasma samples from primarily late-midlife, cognitively unimpaired Wisconsin Registry for Alzheimer's Prevention (WRAP) and Wisconsin Alzheimer's Disease Center (WADRC) participants, we investigated pTau217 agreement with amyloid and tau PET then compared trajectories between participants grouped by baseline pTau217.
View Article and Find Full Text PDFBackground: Mobile phlebotomy is an attractive option for the study of Alzheimer's disease (AD) in rural and underserved populations, but logistics of collecting, and shipping these samples outside clinical settings can introduce additional sources of variability. Knowledge is limited on the impact of field collection on blood-based Alzheimer's disease biomarkers, especially protein stability when dry ice is not available during shipping. Our study looks into the effects of holding plasma samples under refrigeration prior to freezing on AD biomarker concentrations compared to samples that were frozen within one hour of collection as is standard practice.
View Article and Find Full Text PDF